Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

WuXi AppTec IPOs in Shanghai Exchange

publication date: May 7, 2018

WuXi AppTec Co., Ltd. announced its initial public offering in Shanghai stock exchange for 104,198,600 shares of common stock at a price of $3.40 per share. WuXi’s stock price raised 43.98% to $4.89 almost immediately after the stock market opens. The fund collected through this IPO will be used to build drug safety assessment center in Suzhou, expand R&D facilities in Tianjin and WuXi’s headquarter, developing diagnostic projects as well as increasing cash. WuXi will use this IPO fund to further strengthen its capabilities and capacities to decrease drug innovation expenses and improve R&D efficiency. More details....

Stock Symbol: (SHEX: 603259)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
August 25-27, 2020
China Standard Time
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China